Invention Grant
- Patent Title: GP2 isoforms and their use in autoantibody capture
-
Application No.: US16707016Application Date: 2019-12-09
-
Publication No.: US11340235B2Publication Date: 2022-05-24
- Inventor: Dirk Roggenbuck
- Applicant: GA GENERIC ASSAYS GMBH
- Applicant Address: DE Dahlewitz
- Assignee: GA GENERIC ASSAYS GMBH
- Current Assignee: GA GENERIC ASSAYS GMBH
- Current Assignee Address: DE Dahlewitz
- Agency: Agris & Von Natzmer, LLP
- Agent Joyce Von Natzmer
- Priority: EP14157199 20140228
- Main IPC: G01N33/68
- IPC: G01N33/68

Abstract:
The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterized by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilization of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a system and kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD), primary sclerosing cholangitis (PSC), and/or ulcerative colitis (UC).
Public/Granted literature
- US20200209258A1 GP2 ISOFORMS AND THEIR USE IN AUTOANTIBODY CAPTURE Public/Granted day:2020-07-02
Information query
IPC分类: